Research programme: CID based cellular immunotherapies - Bellicum Pharmaceuticals

Drug Profile

Research programme: CID based cellular immunotherapies - Bellicum Pharmaceuticals

Alternative Names: BPX 401; BPZ-2003; CaspaCIDe-enabled CD19 CAR; CaspaCIDe® T Cell immunotherapies - Bellicum Pharmaceuticals; Chemical Induction of Dimerization enabled cellular immunotherapies - Bellicum Pharmaceuticals; CIDeCar#1; DeCIDe® based immunotherapies - Bellicum pharmaceuticals; DS GoCAR-T cells - Bellicum Pharmaceuticals; Dual-Switch CAR-T Cells; Dual-switch GoCAR-T cells - Bellicum Pharmaceuticals; GoCAR-T based immunotherapies - Bellicum Pharmaceuticals

Latest Information Update: 09 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bellicum Pharmaceuticals
  • Class Cancer vaccines; CAR-T cell therapies; Cell therapies; Dendritic cell vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity; Immunostimulants; T lymphocyte replacements; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haematological malignancies
  • No development reported Solid tumours

Most Recent Events

  • 13 Mar 2018 Bellicum Pharmaceuticals has utility patents pending for GoCAR-T technology in USA and regions outside USA
  • 09 Dec 2017 Pharmacodynamics data from a preclinical trial in Haematological malignancies presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2017)
  • 09 Dec 2017 Pharmacodynamics data from a preclinical trial in Cancer presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top